Compare Heron Therapeutics Inc (HRTX) vs iShares TIPS Bond ETF (TIP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs iShares TIPS Bond ETF — how do they compare? Heron Therapeutics Inc trades at $0.37 (market cap $74.04M), while iShares TIPS Bond ETF trades at $104.65 (market cap $14.16B). The key difference: iShares TIPS Bond ETF is far larger — about 191.2× Heron Therapeutics Inc's market cap, and Heron Therapeutics Inc is more actively traded (3,668,095 versus 1,695,817). Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and iShares TIPS Bond ETF for 61 Days on average.
| HRTX | TIP | |
|---|---|---|
Market Cap | $74.04M | $14.16B |
Volume | 3,668,095 | 1,695,817 |
Sector | Health | Fixed Income |
52-Week High | $1.49 | $112.20 |
52-Week Low | $0.27 | $103.98 |
Typical Hold Time | 35 Days | 61 Days |
Enterprise Value | $180.78M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.39, up 17.58% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings performance discussions.
The outlook is mixed: strong analyst support and technical momentum suggest potential upside, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on revenue growth translating to profitability, while key risks include execution challenges and competitive pressures in the biotechnology sector.
TIP trades at $104.24, showing minimal daily movement with a 0.06% gain. Technical indicators signal a bearish trend, while oscillators remain neutral. The ETF's financial ratios are not available in the provided data, limiting fundamental assessment. A dividend of $0.78 is scheduled for August 2026, indicating income potential amid current market volatility driven by rising bond yields and geopolitical tensions.
Outlook is cautious due to bearish technicals and macroeconomic pressures from high Treasury yields. The dividend offers a yield cushion, but investors face risks from bond market instability and inflationary concerns. Monitoring Federal Reserve policy and inflation data is critical for near-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About iShares TIPS Bond ETF
TIP is the flagship ETF for U.S. Treasury Inflation-Protected Securities (TIPS). It tracks an index of government bonds whose principal value adjusts based on the Consumer Price Index (CPI), providing a direct hedge against rising inflation.
Read more on TIP →
